All three tenses have at least two readings, so the archetype blend applies as printed.
Of the nine metrics, 8 read as filed from the record and 1 is an SI estimate, each with its reasoning, its confidence and what would change it on its card.
What did they actually do?
Has it survived what it has been through?
1 warning event since 2017; the latest 2023-04-12.
From the record
Travere Therapeutics, Inc.'s filings since 2017 show 1 warning event: an auditor change (8-K item 4.01, the latest 2023-04-12) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
+15.6% a year over 10 filed years; profitable in 0 of 10.
From the record
Travere Therapeutics, Inc.'s 10 filed years say what it did: revenue went from $134 million in fiscal 2016 to $491 million in fiscal 2025, up 15.6% a year; it rose in 7 of 9 years; the deepest fall was 45% from fiscal 2020 to fiscal 2022; net income was positive in 0 of 10 of those years (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How has it treated the people who own it?
SI estimate 6.1/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Travere Therapeutics, Inc.'s shareholder treatment is put at 6.1 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the top 39% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.
What are they doing right now?
Is it financially healthy right now?
ROE -22%: lost 22¢ per shareholder dollar. Leverage 81%: owes 81¢ per asset dollar.
From the record
Return on equity: in the fiscal year ended 2025-12-31, Travere Therapeutics, Inc. lost about 22 cents for every dollar of shareholders' money, and gross profitability: its products earned about 79 cents per dollar of everything the company owns (revenue less the cost of revenue). Leverage: it owed about 81 cents per dollar of assets, and net share issuance: its share count grew 13.1% over the year (the filed statements).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How strong is its position in its industry?
top 22% of 315 in its family; net margin -5.2%.
From the record
Travere Therapeutics, Inc.'s standing among 315 graded names in its industry family: revenue of $491 million in fiscal 2025 ranks in the top 19% by size; a net margin of -5.2% ranks in the top 27%; revenue growth of 64.9% a year over the last 3 filed years ranks in the top 19% (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are the people in charge doing?
top 26% of 315 in its family for leadership; chief executive since 2019.
From the record
Travere Therapeutics, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Dube, Eric M (CHIEF EXECUTIVE OFFICER, as filed), filing under that title since 2019-01-08, 7.8 years (top 24% of its family); the 16 officers and directors filing in the last fifteen months have been on the record a median of 8.7 years (top 15%); 6 officer or director changes were reported on Form 8-K since 2023-11-13, against the 16 people in charge now (top 39%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are they set up to do next?
How much room does it have to grow?
top 39% of 273 in its family for room to expand.
From the record
Travere Therapeutics, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $93 million against no long-term debt tagged leaves 15.4% of its assets as net cash, bottom 33% of its family; cash from operations less capital spending is 7.7% of revenue (top 23%); a gross margin of 97.9% (top 5%); research spending of 42% of revenue (bottom 40%) (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What could actually drive growth from here?
top 42% of 306 in its family for growth drivers.
From the record
Travere Therapeutics, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 64.9% a year over the last three filed years against 15.6% over all 10, speeding up (top 9% of its family); the newest year grew 110.6% (top 16%); research spending grew -3.2% a year (bottom 42%); capital spending grew -53.8% a year (bottom 17%) (its annual reports). Travere Therapeutics, Inc. reported 3 product lines in fiscal 2025: FILSPARI at $322 million (66%), Tiopronin Products at $88 million (18%), License at $80 million (16%); 2 of 3 grew against the year before (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Did its newest year beat what its own record pointed to?
top 22% of 233 in its family for expectations against reality.
From the record
Travere Therapeutics, Inc.'s newest year against its own record: revenue of $491 million in fiscal 2025 came in 44.2% above the $340 million its prior three years' pace pointed to (top 20% of its family); net income of $26 million against a prior three-year average of $237 million (top 19%); a net margin of -5.2% against losses larger than its revenue before (top 28%) (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made